Head to Head Analysis: Allurion Technologies (NYSE:ALUR) and Metastat (OTCMKTS:MTST)

Allurion Technologies (NYSE:ALUR) and Metastat (OTCMKTS:MTST) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk.

Earnings & Valuation

This table compares Allurion Technologies and Metastat”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allurion Technologies	$32.11 million	0.45	-$7.20 million	($10.56)	-0.11
Metastat	N/A	N/A	N/A	N/A	N/A

Metastat has lower revenue, but higher earnings than Allurion Technologies.

Institutional & Insider Ownership

21.4% of Allurion Technologies shares are owned by institutional investors. 8.1% of Allurion Technologies shares are owned by insiders. Comparatively, 8.5% of Metastat shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Allurion Technologies has a beta of -0.43, suggesting that its share price is 143% less volatile than the S&P 500. Comparatively, Metastat has a beta of 287.07, suggesting that its share price is 28,607% more volatile than the S&P 500.

Profitability

This table compares Allurion Technologies and Metastat’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Allurion Technologies	-199.96%	N/A	-77.13%
Metastat	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Allurion Technologies and Metastat, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allurion Technologies	1	1	2	0	2.25
Metastat	0	0	0	0	0.00

Allurion Technologies currently has a consensus price target of $7.33, indicating a potential upside of 524.11%. Given Allurion Technologies’ stronger consensus rating and higher possible upside, equities analysts plainly believe Allurion Technologies is more favorable than Metastat.

Summary

Allurion Technologies beats Metastat on 5 of the 9 factors compared between the two stocks.

About Allurion Technologies

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.

About Metastat

MetaStat, Inc., a precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. The company is developing novel drug candidates and companion diagnostic tests that target the MENA pathway. Its product candidates include MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures expression of the pro-metastatic MENA protein splice-variant; companion diagnostic to predict RTK inhibitor drug responses and anti-microtubule drug responses; liquid blood-based biopsy to enhance cancer diagnosis and optimize patient care; MetaSite Breast assay, an immunohistochemistry test that measures micro-anatomical intravasat at blood vessels within the tumor microenvironment ion sites; and prognostic diagnostic to predict risk of cancer metastasis. The company’s therapeutic targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. MetaStat, Inc. is based in Boston, Massachusetts.